Real-World Molecular Subtypes and Characteristics of Breast Cancer in Belgium: Insights from Routinely Collected Data [BE-REAST]

Study identification

• EU PAS number:
  EUPAS1000000398
• Study ID:
  1000000398
• Official title and acronym:
  Real-World Molecular Subtypes and Characteristics of Breast Cancer in Belgium: Insights from Routinely Collected Data [BE-REAST]
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  This multicenter study describes molecular subtypes and characteristics of Belgian patients with breast cancer by leveraging natural language processing and the OMOP common data model.
• Study status:
  Finalised

Research institutions and networks

Institutions

AZ Maria Middelares General Hospital

Belgium

AstraZeneca

Universitair Ziekenhuis Antwerpen (UZA)

Belgium

LynxCare Clinical Informartics

Belgium

Algemeen Ziekenhuis Groeninge

Study timelines

Date when funding contract was signed

Actual:16/11/2022

Study start date

Actual:27/10/2023

Date of final study report

Planned:31/12/2023

Actual:10/06/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca BeLux

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable